Proteomics International Laboratories (PIQ) Investor presentation summary

Company overview

• Integrates proteomics expertise with accredited labs to deliver validated diagnostic solutions for earlier and more precise disease detection.

• Focuses on minimally invasive, blood-based prognostic and diagnostic tests for chronic, high-burden, underdiagnosed diseases.

• Operates certified labs in Australia and the USA, ensuring regulated testing across key markets.

• Board and leadership bring deep experience in commercial growth, regulatory pathways, and global market development.

Commercial strategy and execution

• Transitioned from research to disciplined commercial execution, prioritizing validated product launches and capital management.

• Implements distributor-led business models for faster adoption, lower risk, and capital efficiency.

• Focuses on securing reimbursement in Australia and the USA through structured pathways combining private pay and evidence generation.

• Allocates capital to support commercial growth, product performance, and operational efficiency.

Product portfolio and market potential

• Four main tests: Promarker D (diabetes-related kidney disease), Promarker Eso (oesophageal cancer), Promarker Endo (endometriosis), and OxiDx (oxidative stress platform).

• Each test targets significant unmet clinical needs with strong intellectual property protection.

• Combined annual serviceable obtainable market (SOM) for the three main tests is substantial in both Australia and the USA.

• Promarker D: 20,000 SOM in Australia, 390,000 in the USA; Promarker Eso: 15,000 in Australia, 240,000 in the USA; Promarker Endo: 50,000 in Australia, 360,000 in the USA.

• OxiDx targets 60,000 tests in Australia and 1.2 million in the USA, focusing on elite athletes and specialized applications.